Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France

Tran, Viet‐Thi

doi:10.2139/ssrn.3932953

Cited by 35 publications

(28 citation statements)

References 14 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…His findings were consistent with Ayoub, who observed that the first dose of vaccine was significantly associated with a 13% decrease in the development of long COVID symptoms with sustained improvement after the second dose over the median follow-up for 67 days [ 8 ]. These findings were consistent with other studies by Strain and Tran [ 15 , 16 ].…”

Section: Discussionsupporting

confidence: 94%

See 1 more Smart Citation

COVID-19 Vaccine and Long COVID: A Scoping Review

Mumtaz¹,

Sheikh

Khan³

et al. 2022

Life

View full text Add to dashboard Cite

As the COVID-19 pandemic progresses, changing definitions and therapeutics regarding the post-acute sequela of COVID-19, particularly long COVID, have become a subject of great interest and study. The study aims to describe the pathophysiology and discuss different therapeutic agents currently available for long COVID. Another objective is to assess comparative efficacy between different types of vaccines on symptoms of long COVID. A preliminary search was conducted using Ovid Medline, Embase, medRxiv, and NIH COVID-19 portfolios. A total of 16 studies were included in our review. Despite some of the data showing variable results, most of the vaccinated patients reported improvement in long COVID symptoms with no significant difference between various types of vaccines. Further trials are needed to better identify the comparative efficacy of vaccines for long COVID and ascertain other therapeutic modalities.

show abstract

Section: Discussionsupporting

confidence: 94%

“…A prospective cohort study conducted by Tran et al [ 16 ] recruited 910 participants who either had confirmed or highly suspected COVID-19 infection and were followed for 120 days. A total of 455 patients were vaccinated and were matched with 455 unvaccinated patients.…”

Section: Resultsmentioning

confidence: 99%

COVID-19 Vaccine and Long COVID: A Scoping Review

Mumtaz¹,

Sheikh

Khan³

et al. 2022

Life

View full text Add to dashboard Cite

show abstract

“…To date no antiviral or immunomodulatory drug has proven effective for the treatment of long COVID in trials. Some preliminary reports suggest COVID-19 vaccination might improve symptoms in some people, 18,19 supporting the notion of a possible role for persistent viral reservoirs, circulating virus fragments, or both in long COVID. 19 The COVID-19 pandemic has shown the power and necessity of large-scale, multicentre, adaptive platform trials and applying these approaches to long COVID will help accelerate development of an evidence base for disease management.…”

Section: Global Surveillance Research and Collaboration Needed To Improve Understanding And Management Of Long Covidmentioning

confidence: 87%

“…Some preliminary reports suggest COVID-19 vaccination might improve symptoms in some people, 18,19 supporting the notion of a possible role for persistent viral reservoirs, circulating virus fragments, or both in long COVID. 19 The COVID-19 pandemic has shown the power and necessity of large-scale, multicentre, adaptive platform trials and applying these approaches to long COVID will help accelerate development of an evidence base for disease management. Importantly, these trials will need to include centres across various settings with different resource availabilities, such as in WHO's Solidarity and the Recovery and REMAP-CAP treatment trials.…”

Section: Global Surveillance Research and Collaboration Needed To Improve Understanding And Management Of Long Covidmentioning

confidence: 87%

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID

et al. 2021

View full text Add to dashboard Cite

“…Our surveys took place when vaccinations were becoming available to the public. Since vaccination for COVID-19 not only reduces health care utilization and mortality risk, it also appears to reduce long COVID-19 symptoms at 120 days [28], knowledge of vaccination status would be useful in interpreting these results. Unfortunately, our original protocol did not provide for a query on vaccination status, so we cannot evaluate whether vaccinations were a significant factor in these outcomes.…”

Section: Discussionmentioning

confidence: 99%

Post-COVID-19 Condition and Health Status

Kaur

MICHALOPOULOS

CARPE

et al. 2022

COVID

View full text Add to dashboard Cite

Background: Observational studies of the long-term effects of COVID-19 infection generally focus on individual symptoms rather than health status. Objective: Longitudinal assessment of general health status following COVID-19 infection. Design: Observational study, with data collected from two telephone surveys at 32 ± 10 and 89 ± 25 days after discharge from the hospital or emergency department (ED) for a COVID-19 infection. Medicaid or no insurance was our marker of low socioeconomic status (SES). Acute disease severity was determined by summing 10 severity markers (yes-no) from the health encounter. Baseline comorbidity was a modified Charlson Index. Participants: 40 patients. Mean age was 54 ± 15 years, 50% were female, and 40% had low socioeconomic status. Main Measures: (1) the 20-item Medical Outcomes Study Short-Form General Health Survey (SF-20); (2) Dyspnea (modified Medical Research Council); (3) Psychological symptoms (Patient Health Questionnaire for Anxiety and Depression); (4) Cognitive function (Cognitive Change Questionnaire); (5) Fatigue (Short Fatigue Questionnaire); (6) A 10-item review of systems (ROS) questionnaire. Key Results: Percentages with abnormal symptoms at the first and second surveys were (respectively): Dyspnea (40, 33), Fatigue (53, 50), Anxiety (33, 18), Depression (20, 10), PHQ-4 Composite (25, 13), and Cognitive (18, 10). Mean scores on the SF-20 subscales, Physical Functioning, Role Functioning, Social Functioning, Health Perception, Mental Health, and Pain were numerically lower than means from a published study of elderly outpatients. With the exception of Pain, all SF-20 subscale scores improved significantly by the second survey. In multivariable analyses, dyspnea was predictive of impairment in all SF-20 subscales at the second survey. Conclusions: COVID-19 infection causes persistent abnormality across multiple patient-reported outcome areas, including health status. The persistence of impairment in each health status component is influenced by baseline dyspnea.

show abstract

Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France

Cited by 35 publications

References 14 publications

COVID-19 Vaccine and Long COVID: A Scoping Review

COVID-19 Vaccine and Long COVID: A Scoping Review

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID

Post-COVID-19 Condition and Health Status

Contact Info

Product

Resources

About